Latest News on BMY

Financial News Based On Company


Advertisement
Advertisement

3 Big Pharma Dividend Stocks Built for Retirement Income

https://247wallst.com/investing/2026/11/19/3-big-pharma-dividend-stocks-built-for-retirement-income/
This article highlights three big pharmaceutical companies—Bristol Myers Squibb, Novartis, and Sanofi—as strong dividend stocks suitable for retirement income, emphasizing their ability to maintain and grow dividends despite patent cliffs. It examines each company's dividend safety, growth catalysts, and potential risks, noting that all three fund their payouts from diversified global drug portfolios and have strong free cash flow coverage. The article also points out differences in payment frequency and currency impacts for U.S. investors.

AbbVie and Disco ink $2.5bn pact for next-generation cancer bispecifics

https://finance.yahoo.com/news/abbvie-disco-ink-2-5bn-153340392.html
AbbVie has partnered with German biotech Disco Pharmaceuticals in a deal potentially worth up to $2.5 billion, focusing on developing bispecific cancer therapies for solid tumors. AbbVie will pay $40 million upfront, with additional milestone payments and royalties, to leverage Disco's DISCOtech platform for designing selective bispecifics like AND-gated antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). This collaboration aims to address unmet needs in solid tumor indications by developing therapies with a wider therapeutic window and reduced off-tumor toxicity.

Evotec, Bristol Myers Squibb Advance Second Molecular Glue Drug to Clinic

https://www.contractpharma.com/breaking-news/evotec-bristol-myers-squibb-advance-second-molecular-glue-drug-to-clinic/
Evotec and Bristol Myers Squibb have achieved another significant milestone in their protein degradation collaboration with the FDA's acceptance of an Investigational New Drug (IND) application for a second molecular glue drug candidate. This cereblon E3 ligase modulator (CELMoD) is expected to begin Phase 1 clinical testing in 2027, building on the success of their first candidate which entered Phase 1 in March 2026. The partnership, which began in 2018, leverages Evotec's advanced screening and AI capabilities with Bristol Myers Squibb's CELMoD library to develop novel therapeutics for oncology and other diseases.

Vogenx Set to Join the Russell 2000(R), Russell 3000(R), and Russell Microcap(R) Indexes

https://www.stocktitan.net/news/VOGX/vogenx-set-to-join-the-russell-2000-r-russell-3000-r-and-russell-smt5z1vji9ls.html
Vogenx (Nasdaq:VOGX) is scheduled to join the Russell 2000®, Russell 3000®, and Russell Microcap® Indexes as part of FTSE Russell's December 2026 semi-annual reconstitution. This inclusion, effective after U.S. equity markets close on December 11, 2026, is expected to increase Vogenx's visibility with institutional and index-based investors. The company is a clinical-stage developer focused on novel therapeutics for metabolic and gastrointestinal diseases, including its lead candidate mizagliflozin for post-bariatric hypoglycemia.

The Escalator: Bristol Myers Squibb, Moon Rabbit, Merck and more

https://www.mmm-online.com/news/the-escalator-bristol-myers-squibb-moon-rabbit-merck-and-more/
This article details recent leadership changes across the pharma, biotech, and medical marketing industries. Key appointments include new presidents and chief officers at Moon Rabbit, a new CEO at OncoNano Medicine, and executive elevations at Bristol Myers Squibb and LEO Pharma. Merck also announced board changes, and the article touches on various departures and miscellaneous industry news, such as investigations and lawsuits.
Advertisement

Merck & Co., Inc. (NYSE:MRK) Stock Bumped Up to "Hold" by Zacks Research

https://www.marketbeat.com/instant-alerts/analyst-merck-co-inc-nyse-mrk-stock-bumped-up-to-hold-by-zacks-research-2026-11-19/
Zacks Research has upgraded Merck & Co., Inc. (NYSE:MRK) from a "strong sell" to a "hold" rating. The pharmaceutical company recently reported strong quarterly earnings, beating analyst estimates for both EPS and revenue. Despite an insider sale by EVP Richard Deluca, overall analyst sentiment remains a "Moderate Buy" with an average price target of $155.74.

AbbVie Pays $2.54 Billion to Partner With Germany's Disco, Staking a Claim in Solid-Tumor Bispecific Antibodies

https://finance.biggo.com/news/d5aa9063-9e8d-4371-827c-847a96e23c7d
AbbVie has entered into an option and license agreement with Disco Pharmaceuticals, potentially worth up to $2.54 billion, to develop "AND-gated" bispecific antibodies for solid tumors. Disco will receive a $40 million upfront payment and milestone payments, focusing on research and discovery using its DiscoTech platform. This collaboration aims to create precision medicines that selectively target cancer cells while minimizing harm to healthy tissue, building on AbbVie's existing ventures in the bispecific antibody space.

Bristol Myers Squibb to present blood cancer data at ASH 2026

https://www.streetinsider.com/Corporate+News/Bristol+Myers+Squibb+to+present+blood+cancer+data+at+ASH+2026/27372751.html
Bristol Myers Squibb (NYSE: BMY) announced plans to present over 90 disclosures, including 24 oral presentations, from its hematology portfolio at the 68th American Society of Hematology Annual Meeting in December 2026. Key presentations will include Phase 3 results for Zenbexus in relapsed/refractory multiple myeloma, five-year follow-up data for Breyanzi in relapsed or refractory large B-cell lymphoma, and first-in-human data for a dual-targeting CAR T cell therapy. The company will also feature data on golcadomide for follicular lymphoma and Reblozyl for myeloid disorders, as well as Phase 3 data for mezigdomide in multiple myeloma.

Texas awarded cancer grants to 12 projects from 207 applications; Marker received $16.2 million.

https://www.stocktitan.net/news/MRKR/marker-therapeutics-awarded-16-2-million-cprit-grant-to-advance-mt-tn0kdqiqpjcw.html
Marker Therapeutics (MRKR) has been awarded a $16.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). This non-dilutive funding will advance the company's MT-601 (neldaleucel) therapy into a Phase 2 APOLLO study for patients with relapsed or refractory large B-cell lymphoma following CD19-directed CAR-T therapy. The grant was part of a highly competitive funding cycle where CPRIT received 207 applications and awarded $74.3 million to 12 projects.

Codexis management's conference chat will stream live online Dec. 2

https://www.stocktitan.net/news/CDXS/codexis-to-participate-in-piper-sandler-38th-annual-healthcare-x56r5oriuqj6.html
Codexis (CDXS) announced its participation in the Piper Sandler 38th Annual Healthcare Conference, scheduled for December 1-3, 2026, in New York City. Management will host a fireside chat on December 2 at 3:00 p.m. ET, which will be available via live webcast and a 90-day replay on the company’s investor relations website. The company aims to highlight its enzymatic solutions for therapeutics manufacturing, including its ECO Synthesis® Manufacturing Platform.
Advertisement

Debt fell to $225M at Upland Software (UPLD), which is targeting a lower balance for fiscal 2028.

https://www.stocktitan.net/sec-filings/UPLD/8-k-upland-software-inc-reports-material-event-2851128ebb01.html
Upland Software (UPLD) reported a significant reduction in total debt, falling from $482 million at the start of FY24 to $225 million as of September 30, 2026, marking $257 million in debt repaid. The company outlined a three-phase plan focused on simplifying, deleveraging, stabilizing, expanding, and growing, with targets for FY28 including approximately $185 million in total debt and a net leverage of around 2.5x. Upland's investor presentation emphasized its durable customer base, strong margins, and strategic focus on AI-led growth by leveraging its extensive enterprise knowledge and content.

Evotec and Bristol Myers Squibb secure second IND acceptance for protein degrader

https://www.europeanpharmaceuticalreview.com/news/evotec-and-bristol-myers-squibb-secure-second-ind-acceptance-for-protein-degrader/2137032.article
Evotec and Bristol Myers Squibb have received a second Investigational New Drug (IND) acceptance from the FDA for a molecular glue degrader developed through their strategic partnership. This candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter Phase I clinical trials in 2027. This marks the second successful IND acceptance from their collaboration, which focuses on developing molecular glue degraders for oncology and other indications.

Full Truck Alliance approved an about $87.5 million dividend, payable around Jan. 21.

https://www.stocktitan.net/news/YMM/full-truck-alliance-co-ltd-announces-third-quarter-2026-unaudited-ddkm3frwq3x5.html
Full Truck Alliance (NYSE: YMM) reported a 6.8% year-over-year increase in net revenue and a 49.0% rise in net income for Q3 2026. The company's board approved a cash dividend of approximately $87.5 million, or $0.0840 per ADS, to be paid around January 21, 2027. Despite positive financial results, the non-performing loan ratio increased to 4.7%, attributed to delinquent loans and a reduced loan balance.

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

https://investingnews.com/evotec-and-bristol-myers-squibb-advance-strategic-protein-degradation-partnership-with-second-ind-acceptance/
Evotec and Bristol Myers Squibb have achieved a second Investigational New Drug (IND) acceptance from the U.S. FDA for a molecular glue candidate, expanding their strategic protein degradation partnership. This achievement demonstrates the productivity of their collaboration, with the new cereblon E3 ligase modulator (CELMoD) expected to enter a Phase 1 clinical trial in 2027, following the first candidate's entry into trials in March 2026. The partnership leverages Evotec's multi-omics screening and AI-supported data analytics with Bristol Myers Squibb's CELMoD agent library to develop novel molecular glue degraders for high-value oncology targets and other unmet medical needs.

Evotec and Bristol Myers Squibb: Second Molecular Glue Drug Candidate's IND Accepted by FDA, Shares Rise 2% Intraday

https://finance.biggo.com/news/5414b771-56d0-4725-834c-ce6c2bbcf71c
Evotec announced that the FDA has accepted the Investigational New Drug (IND) application for its second molecular glue drug candidate developed in collaboration with Bristol Myers Squibb. This cereblon E3 ligase modulator (CELMoD) is slated to begin Phase 1 clinical trials in 2027, following the first candidate which started trials in March 2026. Evotec's U.S.-listed shares saw an intraday rise of approximately 2% on the news, validating the reproducibility of their drug discovery platform, though investors remain cautious about the timeline to revenue generation.
Advertisement

Omnicom retains the Bristol Myers Squibb US media account

https://adage.com/agencies/accounts-in-review/aa-bristol-myers-squibb-retains-omnicom-media/
Bristol Myers Squibb has decided to retain Omnicom Media for its US media account following a review. This decision comes after the pharmaceutical giant had previously worked with IPG Mediabrands. The article also mentions other featured stories related to creative strategy, the CMO role, and media planning.

Evotec shares rise after second IND acceptance with Bristol Myers

https://www.investing.com/news/stock-market-news/evotec-shares-rise-after-second-ind-acceptance-with-bristol-myers-5038104
Evotec SE shares increased by 2% following the U.S. FDA's acceptance of a second Investigational New Drug application for its protein degradation partnership with Bristol Myers Squibb. This drug candidate, a cereblon E3 ligase modulator, is slated to begin Phase 1 clinical trials in 2027, building on a collaboration that commenced in 2018 and expanded in 2022. The partnership leverages Evotec’s multi-omics screening and AI-supported data analytics with Bristol Myers Squibb’s CELMoD agent library to develop molecular glue degraders.

Alteogen clears US patent hurdle as Merck wins all 14 challenges vs Halozyme

https://www.kedglobal.com/bio-pharma/newsView/ked202611190007
South Korea's Alteogen Inc. has overcome a significant US patent challenge after its partner Merck & Co. won all 14 legal challenges against Halozyme Therapeutics Inc. This victory is crucial for Alteogen, as its licensing agreement with Merck includes up to $1 billion in milestone payments linked to sales targets.

Key facts: Bristol Myers Squibb Advances CELMoD; Shares ADEPT Findings

https://www.tradingview.com/news/tradingview:53d0fff945a16:0-key-facts-bristol-myers-squibb-advances-celmod-shares-adept-findings/
Bristol Myers Squibb (BMY) and Evotec received FDA acceptance for a second IND under their molecular glue partnership, with a CELMoD candidate expected to enter Phase 1 trials in 2027. Additionally, Bristol Myers Squibb shared preliminary ADEPT trial findings at an Alzheimer’s disease conference, though double-blind treatment period results remain blinded.

AbbVie Signs $2.5B Bispecific Cancer Therapy Deal with Disco Pharma

https://www.globalbankingandfinance.com/abbvie-expands-bispecific-cancer-med-push-up-2-5-billion/
AbbVie has entered into an agreement with Disco Pharmaceuticals, potentially worth up to $2.54 billion, to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive an upfront payment of $40 million and could earn up to $2.5 billion in milestone payments and royalties. The collaboration focuses on "AND-gated" bispecific therapeutics designed to target cancer cells more precisely by recognizing two proteins simultaneously, thereby minimizing harm to healthy tissue.
Advertisement

Evotec secures second FDA clearance under BMS partnership

https://grafa.com/news/united-states/evotec-secures-second-fda-ind-acceptance-under-bristol-myers-squibb-partnership
Evotec SE announced that the FDA has accepted a second Investigational New Drug (IND) application under its protein degradation partnership with Bristol Myers Squibb, allowing another experimental candidate targeting cereblon to enter clinical development. This new candidate, a cereblon E3 ligase modulator (CELMoD), is expected to enter Phase 1 trials in 2027. This marks a significant step in expanding the companies' clinical pipeline in targeted protein degradation, following the first candidate's entry into Phase 1 in March 2026.

AbbVie inks up to $2.54B bispecific cancer drug deal with DISCO Pharma

https://seekingalpha.com/news/4674531-abbvie-inks-up-to-254b-bispecific-cancer-drug-deal-with-disco-pharma
AbbVie has announced a collaboration with DISCO Pharmaceuticals, involving an upfront payment and potential milestone payments totaling up to $2.54 billion. This deal aims to develop new bispecific cancer treatments, expanding AbbVie's early-stage pipeline in this therapeutic area.

Evotec SE (EVT) Reports Second IND Acceptance; Phase 1 Expected in 2027

https://www.tradingview.com/news/tradingview:4d73b267f5411:0-evotec-se-evt-reports-second-ind-acceptance-phase-1-expected-in-2027/
Evotec SE announced that the FDA has accepted a second Investigational New Drug (IND) application for its protein degradation partnership with Bristol Myers Squibb, with Phase 1 trials expected to commence in 2027. This follows the first candidate from the collaboration entering Phase 1 in March 2026. The development represents a mid-cycle update to a partnership that began in 2018 and expanded in 2022.

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

https://www.quantisnow.com/insight/evotec-and-bristol-myers-squibb-advance-strategic-protein-degradation-partnership-6799641
Evotec and Bristol Myers Squibb have achieved a second Investigational New Drug (IND) acceptance from the FDA for a molecular glue candidate, advancing their protein degradation partnership. This candidate, a cereblon E3 ligase modulator, is expected to enter Phase 1 trials in 2027. The first candidate from this collaboration entered a Phase 1 trial for advanced clear cell renal cell carcinoma in March 2026.

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

https://live.euronext.com/en/financial-news/abbvie-expands-bispecific-cancer-med-push-25-billion-deal-germanys-disco
AbbVie has entered into an agreement with Germany's Disco Pharmaceuticals, committing up to $2.54 billion to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, along with tiered royalties, for its AND-gated bispecific therapeutics. This early-stage collaboration focuses on developing treatments that target cancer cells only when two specific proteins are present simultaneously, aiming to minimize harm to healthy tissue.
Advertisement

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

https://www.reuters.com/legal/transactional/abbvie-expands-bispecific-cancer-med-push-with-up-25-billion-deal-with-germanys-2026-11-19/
AbbVie has agreed to a deal with Germany's Disco Pharmaceuticals worth up to $2.54 billion to develop next-generation bispecific cancer therapies. This collaboration focuses on "AND-gated" bispecific therapeutics for solid tumors, designed to target cancer cells more precisely by requiring the simultaneous presence of two target proteins. Disco will handle research and discovery, with AbbVie having exclusive licensing rights for further development.

PharmaLogic buys Lantheus' New Jersey radiopharma plant with a supply deal attached

https://www.marketscale.com/industries/sciences/pharmalogic-buys-lantheus-new-jersey-radiopharma-plant-with-a-supply-deal-attached
PharmaLogic is acquiring Lantheus' contract manufacturing unit and its radiopharmaceutical plant in Springfield, New Jersey. This deal includes a long-term supply agreement for PharmaLogic's Agilera unit to manufacture lutetium Lu 177 dotatate for Lantheus. The acquisition positions Agilera to expand its radioligand therapy CDMO services, adding a crucial US-based theranostic manufacturing site to its existing European operations.

Evotec and Bristol Myers Squibb get second FDA IND clearance

https://www.streetinsider.com/Corporate+News/Evotec+and+Bristol+Myers+Squibb+get+second+FDA+IND+clearance/27371949.html
Evotec SE announced that the FDA has accepted a second investigational new drug (IND) application from its protein degradation partnership with Bristol Myers Squibb. This second candidate is a cereblon E3 ligase modulator (CELMoD) and is slated to begin Phase 1 clinical trials in 2027. This milestone demonstrates the productivity of their collaborative discovery platform, which combines Evotec's multi-omics screening and AI-supported data analytics with Bristol Myers Squibb's CELMoD agent library.

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany’s Disco

https://kfgo.com/2026/11/19/abbvie-expands-bispecific-cancer-med-push-with-up-to-2-5-billion-deal-with-germanys-disco/
AbbVie has agreed to a deal worth up to $2.54 billion with Germany's Disco Pharmaceuticals to develop next-generation bispecific cancer therapies for solid tumors. Disco will receive $40 million upfront and up to $2.5 billion in milestone payments, plus royalties, for its AND-gated bispecific therapeutics. This early-stage partnership aims to create treatments that specifically target cancer cells by requiring two proteins to be present simultaneously, thereby potentially reducing harm to healthy tissue.

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors

https://www.marketwatch.com/data-news/bristol-myers-squibb-co-stock-underperforms-wednesday-when-compared-to-competitors-83df4b85-7123a763749e?mod=goog_fin_scmw
Shares of Bristol Myers Squibb Co. (BMY) fell 2.92% on Wednesday, closing at $59.56, marking its third consecutive day of losses. This underperformance occurred during a broader market decline, with the S&P 500 Index (SPX) dropping 0.23% and the Dow Jones Industrial Average (DJIA) falling 1.11%.
Advertisement

BMS' ph. 3 Alzheimer's psychosis teaser builds confidence in Cobenfy expansion plan

https://www.fiercepharma.com/pharma/bms-ph-3-alzheimers-agitation-teaser-builds-confidence-cobenfy-expansion-plan
Bristol Myers Squibb has released preliminary findings from its late-stage Adept program for Cobenfy, showing improvements in hallucinations, delusions, and overall disease severity in patients with Alzheimer's psychosis during open-label periods. While full double-blind data is still pending, these early results and long-term safety data are seen as encouraging by analysts, potentially boosting investor confidence in Cobenfy's expansion beyond schizophrenia. The company aims for market expansion after a subdued initial launch for schizophrenia and will continue to report data in 2027.

A one-time $5.50-per-share dividend is due Jan. 8 for Republic Bancorp's Class A holders.

https://www.stocktitan.net/news/RBCAA/republic-bancorp-inc-declares-regular-quarterly-cash-dividend-and-jornw883ijov.html
Republic Bancorp, Inc. announced a regular quarterly cash dividend of $0.495 per share on Class A Common Stock and $0.45 per share on Class B Common Stock, payable January 15, 2027. Additionally, the company declared a one-time special cash dividend of $5.50 per share on Class A Common Stock and $5.00 per share on Class B Common Stock, payable January 8, 2027. These dividends reflect the company's strong capital position and commitment to shareholder value, with Republic Bancorp expected to remain well-capitalized after the special dividend payment.

Royal Gold adds mining veteran to board, plans declassification

https://www.streetinsider.com/Board+Changes/Royal+Gold+adds+mining+veteran+to+board%2C+plans+declassification/27370170.html
Royal Gold, Inc. has appointed Harry Kenyon-Slaney, a mining industry veteran with over 40 years of experience, to its board of directors, expanding the board to eight members. The company's board also approved a proposed amendment to declassify the board, which will be submitted for stockholder approval at the 2027 Annual Meeting. If approved, all directors would stand for annual election starting at the 2030 Annual Meeting, moving away from the current staggered three-year terms.

Royal Bank Of Canada (RY): Structured notes on Bristol-Myers Squibb stock due November 2029

https://www.quantisnow.com/insight/sec-form-fwp-filed-by-royal-bank-of-canada-6798540
Royal Bank of Canada (RBC) has filed for 3-year auto-callable notes on Bristol-Myers Squibb (BMY) stock, offering a minimum contingent coupon of 10.50% per annum, due November 30, 2029. These notes provide quarterly contingent coupons if BMY stock meets a certain threshold and can be called early. However, investors face risks including the potential loss of principal if BMY's value falls below a barrier and returns being capped.

C4 Therapeutics' Andrew Hirsch bets a microgram-dose degrader can beat CAR-T durability in myeloma

https://finance.biggo.com/news/b119e7f1f23ed123
C4 Therapeutics CEO Andrew Hirsch believes protein degradation, using the cell's own recycling system, can target "undruggable" proteins. Their lead asset, cemsidomide, a highly selective molecular glue, is in a pivotal-intent trial for myeloma, dosed at just 100 micrograms. Hirsch aims to combine cemsidomide with Pfizer's elranatamab to achieve CAR-T-level durability by countering T-cell exhaustion, with combination data expected in mid-2027 and a potential filing by end-2028.
Advertisement

Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy?

https://www.tradingview.com/news/zacks:f5de8e3bc094b:0-bristol-myers-vs-merck-which-big-pharma-stock-is-the-better-buy/
This article compares Bristol Myers Squibb (BMY) and Merck & Co. (MRK), two major pharmaceutical companies, to determine which offers a better investment opportunity. While BMY has a higher dividend yield and attractive growth from its "Growth Portfolio," it faces risks from generic competition and high debt. MRK, despite the impending patent expiration of its blockbuster drug Keytruda, shows stronger stock performance, diversified growth drivers, an expanding pipeline, and strategic acquisitions, making it the more compelling choice for investors.

Bristol Myers Squibb Says KarXT Reduces Hallucinations and Delusions In Preliminary Alzheimer's Trials

https://www.benzinga.com/markets/biotech/26/11/63400914/bristol-myers-squibb-says-karxt-reduces-hallucinations-and-delusions-in-preliminary-alzheimers-trials
Bristol Myers Squibb announced preliminary Phase 3 data for KarXT, showing its effectiveness in reducing psychosis symptoms like hallucinations and delusions in Alzheimer's disease patients. The treatment, evaluated in the ADEPT-1 and ADEPT-3 trials, demonstrated general tolerability and no new safety signals over short and long-term periods. KarXT was previously approved in September 2024 for schizophrenia, marking a significant advancement in medicine.

CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions

https://www.biospace.com/drug-development/CTAD-2026-bms-cobenfy-eases-alzheimer's-psychosis-as-expected-but-safety-events-raise-questions
Bristol Myers Squibb (BMS) presented early data for its Alzheimer's disease psychosis trials of KarXT (Cobenfy) at the CTAD conference, showing reductions in hallucinations and delusions. While efficacy signals were encouraging, BMO Capital Markets noted that investors are awaiting more robust randomized results due to questions raised by the safety data and patient discontinuations. The muscarinic antipsychotic, approved for schizophrenia in 2024, has faced market struggles due to side effects, but BMS hopes the Alzheimer's psychosis indication will significantly boost sales.

BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions

https://www.biospace.com/drug-development/bms-cobenfy-eases-alzheimers-psychosis-as-expected-but-safety-events-raise-questions
Bristol Myers Squibb (BMS) presented early data from its Phase 3 ADEPT program for Cobenfy (KarXT) at the CTAD conference, showing improvements in hallucinations and delusions in Alzheimer's disease psychosis patients. While efficacy signals were encouraging, analysts expressed concerns regarding the high rate of treatment-emergent adverse events (TEAEs) and discontinuations. The full randomized, placebo-controlled data, including relapse prevention, is expected in 2027 after previous delays.

Pfizer leaps into ‘in vivo’ CAR-T with latest China deal

https://www.biopharmadive.com/news/pfizer-starna-in-vivo-cell-therapy-autoimmune-disease-deal/875018/
Pfizer has entered a significant collaboration with Starna Therapeutics, paying $330 million upfront and up to $2.3 billion in milestone payments, to develop "in vivo" cell therapies for autoimmune diseases. This deal marks Pfizer's entry into the competitive "in vivo" CAR-T research space, aiming to reprogram cells inside the body and potentially simplify current "ex vivo" CAR-T processes that require cell harvesting and modification outside the body. The partnership leverages Pfizer's RNA-based medicine expertise and highlights a growing trend among drugmakers to pursue "in vivo" therapies for conditions beyond cancer, including lupus and multiple sclerosis.
Advertisement

CTAD 2026: Biogen, AriBio lead the way in slowing cognitive decline in Alzheimer’s

https://www.biospace.com/drug-development/ctad-2026-biogen-aribio-lead-the-way-in-slowing-cognitive-decline-in-alzheimers
At the 2026 Clinical Trials on Alzheimer’s Disease conference, Biogen and AriBio reported positive results for their Alzheimer's therapies. Biogen's anti-tau therapy, diranersen, showed a 38% slowing of clinical decline over two years, supporting its advancement to Phase 3. AriBio's PDE5 inhibitor, AR1001, achieved success in a Phase 3 trial by slowing clinical decline by 31% in a monotherapy subgroup, with plans to discuss results with the FDA.

Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline?

https://www.tradingview.com/news/zacks:d54a2d82c094b:0-merck-ends-nemtabrutinib-development-what-s-next-for-its-pipeline/
Merck has discontinued the development of nemtabrutinib (MK-1026), an investigational Bruton's tyrosine kinase inhibitor for hematologic malignancies, after a review indicated its potential benefits might not outweigh the risks. Despite this setback, Merck's broader pipeline, particularly in oncology, vaccines, and infectious diseases, remains promising, with several late-stage candidates and an expectation of launching 20 new drugs by 2030. The company anticipates over $70 billion in non-risk-adjusted commercial opportunity from its current pipeline by the mid-2030s, more than double Keytruda's peak sales estimate.

NCPA, CPESN and Bristol Myers Squibb expand stroke prevention program

https://drugstorenews.com/ncpa-cpesn-and-bristol-myers-squibb-expand-stroke-prevention-program
The National Community Pharmacists Association (NCPA), CPESN USA, and Bristol Myers Squibb are tripling the scope of their stroke prevention program due to encouraging initial results. The program utilizes pharmacists and pharmacy technicians to screen for cardiovascular disease and stroke risks, counsel patients, and connect them with necessary social services. The first phase identified nearly 10,000 at-risk patients and made over 20,000 interventions, demonstrating the significant value pharmacists can add to the healthcare system, especially in rural areas.

Erasca and Bristol Myers Squibb to test ERAS-0015 in pancreatic cancer

https://www.streetinsider.com/Corporate+News/Erasca+and+Bristol+Myers+Squibb+to+test+ERAS-0015+in+pancreatic+cancer/27366066.html
Erasca and Bristol Myers Squibb have entered a clinical trial collaboration to evaluate Erasca's ERAS-0015 in combination with Bristol Myers Squibb's navlimetostat for patients with MTAP-deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the trial, while Erasca will supply ERAS-0015, an investigational oral pan-RAS molecular glue that has shown early clinical activity in other solid tumors. This collaboration aims to explore the potential of simultaneously inhibiting RAS and PRMT5 pathways in these specific pancreatic cancers.

Erasca Partners With Bristol Myers Squibb to Evaluate ERAS-0015 Combination Treatment for Pancreatic Cancer

https://finance.yahoo.com/healthcare/articles/erasca-partners-bristol-myers-squibb-114311907.html
Erasca, Inc. has entered a clinical trial collaboration with Bristol Myers Squibb to evaluate a combination treatment for MTAP-deleted pancreatic ductal adenocarcinoma. The study will assess Erasca's investigational drug ERAS-0015 alongside Bristol Myers Squibb's PRMT5 inhibitor, navlimetostat, targeting RAS mutations and PRMT5. This non-exclusive agreement allows both companies to retain rights to their respective compounds, expanding Erasca's clinical development program.
Advertisement

A cancer test can detect 1 cell in 1 million healthy cells. New research will examine its role in treatment decisions.

https://www.stocktitan.net/news/ADPT/adaptive-biotechnologies-highlights-clono-seq-s-central-role-in-98d1tr8wks4n.html
Adaptive Biotechnologies announced that its clonoSEQ test, which detects measurable residual disease (MRD) in cancer patients, will be featured in approximately 100 abstracts at the American Society of Hematology annual meeting. The research highlights clonoSEQ's expanding role in informing treatment decisions across multiple myeloma, chronic lymphocytic leukemia, and diffuse large B-cell lymphoma. The company emphasizes the test's ability to assess long-term treatment response, guide therapy strategies, and potentially identify patients with sustained MRD negativity and survival comparable to the general population.

Olema Oncology Announces Preclinical Data Show Potent Oral KAT6A Degraders Inhibit ER+/HER2- Breast Cancer Growth

https://www.quiverquant.com/news/Olema+Oncology+Announces+Preclinical+Data+Show+Potent+Oral+KAT6A+Degraders+Inhibit+ER%2B%2FHER2-+Breast+Cancer+Growth
Olema Oncology reported promising preclinical data on its selective KAT6A degraders, showing strong antitumor activity and good tolerability in ER+/HER2- breast cancer models. These oral compounds demonstrated potent antiproliferative effects in both ESR1-mutant and wild-type models, leading to significant tumor growth inhibition and regression. The findings suggest KAT6A degradation could be a valuable new therapeutic strategy for breast cancer, complementing Olema's existing KAT6 inhibitor.

At $10.40 apiece, Saba Capital indirectly bought 200 shares of Gabelli Healthcare & WellnessRx Trust (GRX).

https://www.stocktitan.net/sec-filings/GRX/form-4-gabelli-healthcare-wellness-rx-trust-insider-trading-activity-71c739b92efb.html
Saba Capital Management, L.P., a 10% owner of Gabelli Healthcare & WellnessRx Trust (GRX), indirectly purchased 200 common shares at $10.40 each on November 16, 2026. This transaction increased their reported position to 2,196,238 shares, held by funds for which Saba Capital serves as investment manager. The filing indicates a moderate impact and neutral sentiment.

Bristol Myers Squibb (BMY) Gets A Camzyos Boost, Is The Pipeline Optimism Already Priced In?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-bmy/bristol-myers-squibb/news/bristol-myers-squibb-bmy-gets-a-camzyos-boost-is-the-pipelin
Bristol Myers Squibb (BMY) is gaining attention due to new clinical data for Camzyos in pediatric obstructive hypertrophic cardiomyopathy and its broader biopharma pipeline. While short-term momentum has cooled, the company has seen positive share price returns over the last month and year-to-date. Investors are currently reassessing whether the optimism surrounding its pipeline and risk profile is already reflected in the stock's current price of around US$61 per share.

Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat

https://www.quantisnow.com/insight/erasca-enters-into-clinical-collaboration-with-bristol-myers-squibb-to-6797542
Erasca and Bristol Myers Squibb have formed a clinical collaboration to evaluate Erasca's ERAS-0015 in combination with BMS's navlimetostat for patients with MTAP-deleted pancreatic ductal adenocarcinoma. Bristol Myers Squibb will sponsor the Phase 1/2 trial, with Erasca supplying ERAS-0015, while both companies retain their development and commercial rights. The agreement does not include upfront payments, milestones, or royalties, making the financial value for Erasca currently unknown.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement